A new study indicates that deep brain stimulation (DBS) plus best medical therapy markedly improves quality of life of patients with advanced Parkinson disease compared with best medical therapy alone. The frequency of serious adverse events related to DBS was similar to that reported in other DBS trials, underscoring the need for careful patient selection and counseling for this invasive therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells
Cell Research Open Access 22 November 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Williams, A. et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomized, open-label trial. Lancet Neurol. 9, 581–591 (2010).
Weaver, F. et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease. JAMA 301, 63–73 (2009).
Deuschl, G. et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 355, 896–908 (2006).
Moro, E. et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov. Disord. 25, 578–586 (2010).
Gervais-Bernard, H. et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J. Neurol. 256, 225–233 (2009).
Schüpback, W. M. et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J. Neurol. Neurosurg. Psychiatry 76, 1640–1644 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. A. Brodsky has received research funding from Medtronic. J. G. Nutt has received honoraria from Novartis for lectures and honoraria from Addex Pharmaceuticals, Elan Pharmaceuticals, Impax Laboratories, Medtronic, Merck, Neuroderm, Neurogen, Synosia Therapeutics, XenoPort for consulting. He has also received research funding from Merck.
Rights and permissions
About this article
Cite this article
Brodsky, M., Nutt, J. Deep brain stimulation versus best medical therapy for PD. Nat Rev Neurol 6, 530–532 (2010). https://doi.org/10.1038/nrneurol.2010.128
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.128
This article is cited by
-
Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells
Cell Research (2012)
-
Constant-current deep brain stimulation improves symptoms in Parkinson disease
Nature Reviews Neurology (2012)